publication date: Nov. 29, 2016

Testicular Cancer High-Dose Chemo and Stem Cell Transplant Cures Most Relapsed Testis Cancer

Sixty percent of men whose testicular cancer returned were cured with high-dose chemotherapy and a stem cell transplant, according to research published by Indiana University researchers.

Researchers, led by Lawrence Einhorn, IU Distinguished Professor and Livestrong Foundation Professor of Oncology at the IU School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, found that high-dose chemotherapy with carboplatin and etoposide followed by a stem cell transplant using the patients’ own peripheral blood stem cells cured 60 percent of the men, even those with aggressive and advanced disease.

The research was published online in the Journal of Clinical Oncology.

“Our study shows that high-dose chemotherapy and autologous peripheral-blood stem cell transplant is very effective at curing patients with relapsed testicular cancer,” Dr. Einhorn and colleagues wrote.

The researchers studied 364 patients who relapsed after receiving an initial round of chemotherapy and were then treated with high-dose chemotherapy and transplant between 2004 and 2014. It is believed to be the largest single-institution study that evaluated high-dose chemotherapy and peripheral-blood stem cell transplant in patients with relapsed testicular cancer.

The research team pointed out that there is uncertainty regarding the best treatment options for men who relapse. The choices … Continue reading CCL Nov 2016 – High-Dose Chemo and Stem Cell Transplant Cures Most Relapsed Testis Cancer

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.